Published in BMC Infect Dis on June 01, 2006
Nanoparticles reveal that human cervicovaginal mucus is riddled with pores larger than viruses. Proc Natl Acad Sci U S A (2009) 2.13
Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis (2009) 1.81
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
A longitudinal study of vaginal douching and bacterial vaginosis--a marginal structural modeling analysis. Am J Epidemiol (2008) 1.63
Targeting Trojan Horse leukocytes for HIV prevention. AIDS (2010) 1.40
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front Microbiol (2011) 1.33
Amyloid-binding small molecules efficiently block SEVI (semen-derived enhancer of virus infection)- and semen-mediated enhancement of HIV-1 infection. J Biol Chem (2010) 1.26
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses. Infect Immun (2009) 1.24
Susceptibility to genital herpes as a biomarker predictive of increased HIV risk: expansion of a murine model of microbicide safety. Antivir Ther (2009) 1.24
Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS One (2012) 1.16
Identification of personal lubricants that can cause rectal epithelial cell damage and enhance HIV type 1 replication in vitro. AIDS Res Hum Retroviruses (2011) 1.14
Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One (2010) 1.12
Microbicide excipients can greatly increase susceptibility to genital herpes transmission in the mouse. BMC Infect Dis (2010) 1.09
Innate and adaptive anti-HIV immune responses in the female reproductive tract. J Reprod Immunol (2013) 1.09
Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. PLoS One (2012) 1.08
Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles. Pharm Res (2008) 1.04
IgG in cervicovaginal mucus traps HSV and prevents vaginal herpes infections. Mucosal Immunol (2014) 1.02
A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains. Retrovirology (2012) 1.01
Female genital tract secretions and semen impact the development of microbicides for the prevention of HIV and other sexually transmitted infections. Am J Reprod Immunol (2010) 1.00
Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseriagonorrhoeae. Int J Antimicrob Agents (2010) 0.99
HIV-1 infection of female genital tract tissue for use in prevention studies. J Acquir Immune Defic Syndr (2013) 0.99
Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater (2013) 0.95
Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials (2013) 0.94
Protective role of Toll-like receptor 4 in experimental gonococcal infection of female mice. Mucosal Immunol (2011) 0.94
Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety. Antimicrob Agents Chemother (2013) 0.92
Clinical features of bacterial vaginosis in a murine model of vaginal infection with Gardnerella vaginalis. PLoS One (2013) 0.92
Surfactants as microbicides and contraceptive agents: a systematic in vitro study. PLoS One (2008) 0.88
Safety analysis of the diaphragm in combination with lubricant or acidifying microbicide gels: effects on markers of inflammation and innate immunity in cervicovaginal fluid. Am J Reprod Immunol (2009) 0.88
Differences in immunoregulatory cytokine expression patterns in the systemic and genital tract compartments of HIV-1-infected commercial sex workers in Benin. Mucosal Immunol (2008) 0.87
Use of high-resolution confocal imaging of the vaginal epithelial microstructure to detect microbicide toxicity. J Infect Dis (2009) 0.87
Drug-induced reactivation of apoptosis abrogates HIV-1 infection. PLoS One (2013) 0.87
Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action. Drug Dev Ind Pharm (2009) 0.85
Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric (2015) 0.84
In vitro surfactant structure-toxicity relationships: implications for surfactant use in sexually transmitted infection prophylaxis and contraception. PLoS One (2011) 0.84
Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol (2013) 0.84
BLT humanized mice as model to study HIV vaginal transmission. J Infect Dis (2013) 0.84
Effects of benzalkonium chloride on THP-1 differentiated macrophages in vitro. PLoS One (2013) 0.84
Mucosal integrity and inflammatory markers in the female lower genital tract as potential screening tools for vaginal microbicides. Contraception (2011) 0.83
Optical coherence tomography for assessment of microbicide safety in a small animal model. J Biomed Opt (2013) 0.83
Cultivated vaginal microbiomes alter HIV-1 infection and antiretroviral efficacy in colonized epithelial multilayer cultures. PLoS One (2014) 0.83
Convective diffusion of nanoparticles from the epithelial barrier toward regional lymph nodes. Adv Colloid Interface Sci (2013) 0.83
Nanoparticle-based drug delivery to the vagina: a review. J Control Release (2014) 0.83
Quantitative assessment of microbicide-induced injury in the ovine vaginal epithelium using confocal microendoscopy. BMC Infect Dis (2012) 0.82
Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One (2012) 0.82
Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety. J Acquir Immune Defic Syndr (2012) 0.81
New candidate biomarkers in the female genital tract to evaluate microbicide toxicity. PLoS One (2014) 0.81
Image-based noninvasive evaluation of colorectal mucosal injury in sheep after topical application of microbicides. Sex Transm Dis (2013) 0.81
Herpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease. Med Microbiol Immunol (2014) 0.80
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob Agents Chemother (2012) 0.80
Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing. Antimicrob Agents Chemother (2009) 0.79
Infertility as a consequence of spermagglutinating Staphylococcus aureus colonization in genital tract of female mice. PLoS One (2012) 0.78
A Pilot Study Measuring the Distribution and Permeability of a Vaginal HIV Microbicide Gel Vehicle Using Magnetic Resonance Imaging, Single Photon Emission Computed Tomography/Computed Tomography, and a Radiolabeled Small Molecule. AIDS Res Hum Retroviruses (2015) 0.78
Decreased cervical epithelial sensitivity to nonoxynol-9 (N-9) after four daily applications in a murine model of topical vaginal microbicide safety. BMC Pharmacol Toxicol (2012) 0.78
Poly(ethylene glycol) (PEG)-lactic acid nanocarrier-based degradable hydrogels for restoring the vaginal microenvironment. J Control Release (2014) 0.76
In Vivo Rectal Mucosal Barrier Function Imaging in a Large-Animal Model by Using Confocal Endomicroscopy: Implications for Injury Assessment and Use in HIV Prevention Studies. Antimicrob Agents Chemother (2016) 0.75
Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus. Biomacromolecules (2014) 0.75
Topical injury evaluation of the murine colorectal mucosa using confocal endomicrosopy: a valuable method for assessing mucosal injuries associated with risk of pathogen transmission. J Microsc (2016) 0.75
Will vaginal microbicides solve the HIV problem in Africa? Croat Med J (2006) 0.75
Microbicidas Metodo de Prevencion en VIH/SIDA Controlado por Mujeres. Hisp Health Care Int (2009) 0.75
Relationship between nugent score and vaginal epithelial exfoliation. PLoS One (2017) 0.75
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr (2004) 5.94
Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med (2003) 5.71
Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS (2001) 4.76
Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol (2004) 3.92
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis (2001) 2.49
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol (2003) 2.04
Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retroviruses (1998) 1.99
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol (1997) 1.89
Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod (2004) 1.87
Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS (2001) 1.75
Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models. Sex Transm Dis (2001) 1.72
Nonoxynol-9 causes rapid exfoliation of sheets of rectal epithelium. Contraception (2000) 1.72
Microbicides--evaluating multiple formulations of C31G. Contraception (2002) 1.67
Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes. Antimicrob Agents Chemother (2003) 1.59
Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate. Antiviral Res (1999) 1.51
Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother (2004) 1.50
Lubricants containing N-9 may enhance rectal transmission of HIV and other STIs. Contraception (2004) 1.47
The vaginal microflora of pig-tailed macaques and the effects of chlorhexidine and benzalkonium on this ecosystem. Sex Transm Dis (1997) 1.46
Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis (2001) 1.43
In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception (2004) 1.40
In vivo role of nectin-1 in entry of herpes simplex virus type 1 (HSV-1) and HSV-2 through the vaginal mucosa. J Virol (2004) 1.39
Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol (2002) 1.36
A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother (1999) 1.35
The topical microbicide PRO 2000 protects against genital herpes infection in a mouse model. J Infect Dis (1999) 1.32
Distribution of a spermicide containing Nonoxynol-9 in the vaginal canal and the upper female reproductive tract. Hum Reprod (2001) 1.32
The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in-vitro. J Antimicrob Chemother (1993) 1.30
Contraceptive effectiveness and safety of five nonoxynol-9 spermicides: a randomized trial. Obstet Gynecol (2004) 1.29
Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis (2002) 1.25
Effects of nonoxynol-9 on vaginal microflora and chlamydial infection in a monkey model. Sex Transm Dis (1997) 1.23
Entry of inflammatory cells into the mouse vagina following application of candidate microbicides: comparison of detergent-based and sulfated polymer-based agents. Sex Transm Dis (2002) 1.15
Tests of vaginal microbicides in the mouse genital herpes model. Contraception (1997) 1.14
Residence half-life of IgG administered topically to the mouse vagina. Biol Reprod (1996) 1.11
Comparative safety evaluation of the candidate vaginal microbicide C31G. Antimicrob Agents Chemother (2005) 1.03
Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception (2002) 1.01
Nonoxynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception (1998) 1.01
Poly(sodium 4-styrene sulfonate): evaluation of a topical microbicide gel against herpes simplex virus type 2 and Chlamydia trachomatis infections in mice. Clin Microbiol Infect (2003) 1.00
Disruption of the upper female reproductive tract epithelium by nonoxynol-9. Contraception (2003) 1.00
Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. J Infect Dis (1993) 1.00
Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database Syst Rev (2002) 0.97
Toxicity, inflammation, and anti-human immunodeficiency virus type 1 activity following exposure to chemical moieties of C31G. Biomed Pharmacother (2005) 0.95
Effect of polyanionic compounds on intracutaneous and intravaginal herpesvirus infection in mice: impact on the search for vaginal microbicides with anti-HIV activity. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 0.90
Monitoring of rabbit cornea response to dehydration stress by optical coherence tomography. Invest Ophthalmol Vis Sci (2004) 0.85
Pathogenesis of genital herpes simplex virus infection in mice. IV. Quantitative aspects of viral latency. Med Microbiol Immunol (1986) 0.82
Lesson learned and dispelled myths: three-dimensional imaging of the human vagina. Fertil Steril (2004) 0.80
Review: in vitro spermicidal tests. Contraception (1996) 0.80
Sulfated polysaccharides block chlamydia infection in vitro, but do not protect mice from vaginal inoculation. Microb Pathog (1998) 0.78
In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses (2005) 3.89
Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS (2011) 2.86
Immunological microenvironments in the human vagina and cervix: mediators of cellular immunity are concentrated in the cervical transformation zone. Biol Reprod (2005) 2.48
Response to Neisseria gonorrhoeae by cervicovaginal epithelial cells occurs in the absence of toll-like receptor 4-mediated signaling. J Immunol (2002) 1.88
Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci Transl Med (2012) 1.68
Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men. AIDS (2012) 1.56
In vaginal fluid, bacteria associated with bacterial vaginosis can be suppressed with lactic acid but not hydrogen peroxide. BMC Infect Dis (2011) 1.56
Vaginal transmission of cell-associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J Clin Invest (2002) 1.46
Vaginal pH and microbicidal lactic acid when lactobacilli dominate the microbiota. PLoS One (2013) 1.43
Prevalence of sexually transmissible pathogens in semen from asymptomatic male infertility patients with and without leukocytospermia. Fertil Steril (2007) 1.40
A self-sampling method to obtain large volumes of undiluted cervicovaginal secretions. Sex Transm Dis (2003) 1.40
Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia. Biol Reprod (2011) 1.29
Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model. BMC Infect Dis (2005) 1.26
Concentrations and significance of cytokines and other immunologic factors in semen of healthy fertile men. Hum Reprod (2007) 1.26
Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis. Sex Transm Dis (2002) 1.25
Mouse strain-dependent differences in susceptibility to Neisseria gonorrhoeae infection and induction of innate immune responses. Infect Immun (2009) 1.24
Growth of Neisseria gonorrhoeae in the female mouse genital tract does not require the gonococcal transferrin or hemoglobin receptors and may be enhanced by commensal lactobacilli. Infect Immun (2002) 1.24
Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr (2003) 1.23
Cervicovaginal fluid and semen block the microbicidal activity of hydrogen peroxide produced by vaginal lactobacilli. BMC Infect Dis (2010) 1.19
Organotypic human vaginal-ectocervical tissue model for irritation studies of spermicides, microbicides, and feminine-care products. Toxicol In Vitro (2005) 1.16
Cell-associated genital tract virus and vertical transmission of human immunodeficiency virus type 1 in antiretroviral-experienced women. J Infect Dis (2003) 1.11
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog (2013) 1.07
SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans. PLoS One (2011) 1.01
Contraceptive efficacy of a novel spermicidal microbicide used with a diaphragm: a randomized controlled trial. Obstet Gynecol (2007) 1.01
T-lymphocyte profile and total and virus-specific immunoglobulin concentrations in the cervix of HIV-1-infected women. J Acquir Immune Defic Syndr (2007) 0.97
Depletion of CD4+ T cells in semen during HIV infection and their restoration following antiretroviral therapy. J Acquir Immune Defic Syndr (2009) 0.97
Selective suppression of monocyte chemoattractant protein-1 expression by human papillomavirus E6 and E7 oncoproteins in human cervical epithelial and epidermal cells. Int J Cancer (2003) 0.95
A Phase I study of the functional performance, safety and acceptability of the BufferGel Duet. Contraception (2007) 0.93
Detection of implantation-related cytokines in cervicovaginal secretions and peripheral blood of fertile women during ovulatory menstrual cycles. Fertil Steril (2004) 0.92
An acceptability and safety study of the Duet cervical barrier and gel delivery system in Zimbabwe. J Int AIDS Soc (2010) 0.92
Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial. Obstet Gynecol (2011) 0.91
Development of an in vitro alternative assay method for vaginal irritation. Toxicology (2010) 0.87
Microflora changes with the use of a vaginal microbicide. Sex Transm Dis (2002) 0.86
Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action. Drug Dev Ind Pharm (2009) 0.85
Anti-gp120 minibody gene transfer to female genital epithelial cells protects against HIV-1 virus challenge in vitro. PLoS One (2011) 0.84
Implications of blood contamination for assessment of local cellular immunity in the endocervix. AIDS Res Hum Retroviruses (2004) 0.84
Finally, a macaque model for cell-associated SIV/HIV vaginal transmission. J Infect Dis (2010) 0.83
Expression of toll-like receptors in genital tract tissues from normal and HIV-infected men. Am J Reprod Immunol (2011) 0.82
Hormonal contraception and the risks of STI acquisition: results of a feasibility study to plan a future randomized trial. Contraception (2008) 0.82
Separation of human immunodeficiency virus type 1 from motile sperm by the double tube gradient method versus other methods. Fertil Steril (2004) 0.81
Human immunodeficiency virus type-1 episomal cDNA in semen. AIDS Res Ther (2005) 0.80
Human monoclonal antibody stability and activity at vaginal pH. J Reprod Immunol (2002) 0.80
Maternal CD46H*2 and IL1B-511*1 homozygosity in T helper 1-type immunity to trophoblast antigens in recurrent pregnancy loss. Hum Reprod (2005) 0.78
HIV-discordant couples and parenthood: how are we dealing with the risk of transmission? AIDS (2006) 0.77
Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations. Am J Reprod Immunol (2005) 0.76
HIV-1 is undetectable in preejaculatory secretions from HIV-1-infected men on suppressive HAART. AIDS (2016) 0.75
Massive transfusion protocols for patients with substantial hemorrhage. Transfus Med Rev (2011) 0.75
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. J Int AIDS Soc (2016) 0.75